Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

Inghilesi, Andrea L; Gallori, D.; Antonuzzo, Lorenzo; Forte, Paolo; Tomčíková, Daniela; Arena, Umberto; Colagrande, Stefano; Pradella, Silvia; Fani, B.; Gianni, Elena; Boni, Luca; Costanzo, Francesco Di; Marra, Fabio

doi:10.3748/wjg.v20.i3.786

Cited by 23 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nagano et al noticed that the overall median progression-free survival (PFS) of advanced HCC was 2.0 months (40). In addition, the association between sorafenib therapy and longer DFS is largely concordant with previous studies in patients with HCC (25,(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52). In a pilot study by Wang et al (25) that included 31 patients at a high risk of recurrence, sorafenib therapy following hepatic resection significantly improved the time to recurrence as well as the recurrence rate.…”

Section: Discussionsupporting

confidence: 71%

“…Despite the fact that the present results differ from those reported by previous studies (36,52,53), the present data are still solid due to the following reasons. Firstly, in the current study, only patients with a high risk of recurrence were included.…”

Section: Univariate Analysiscontrasting

confidence: 56%

“…In these patients, ECOG PS, extrahepatic spread, macrovascular invasion, and AFP and ALP levels at admission were identified as independent predictors of overall survival (52). In another study of 110 patients with advanced HCC that were treated with sorafenib in Germany, ascites, macrovascular invasion and BCLC stage D were independently associated with overall survival (53).…”

Section: Univariate Analysismentioning

confidence: 99%

See 2 more Smart Citations

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence

Liao

Zheng

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Sorafenib is the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC); however, its therapeutic value in patients with HCC following resection remains controversial. The current retrospective study was undertaken to assess the effects of sorafenib treatment following surgical resection in patients with advanced HCC disease who were at a high risk for recurrence. Between July 2010 and July 2013, a consecutive cohort of 42 patients with advanced HCC and at a high risk of recurrence (i.e., those with portal vein tumor thrombosis, adjacent organ involvement or tumor rupture) who underwent resection were analyzed. The patients were categorized into the sorafenib group (n=14) or the best supportive care (BSC) group (n=28). Although the histological grade, Barcelona Clinic Liver Cancer Stage, tumor size, nodule number and proportion of patients with high serum α-fetoprotein levels were comparable between the sorafenib and BSC groups, those receiving sorafenib following resection had significantly longer disease-free survival (DFS) of 5.2 months [95% confidence interval (CI), 1.2-9.2 months] compared with the BSC group [1.8 months (95% CI, 0.6-3.0 months)]. No differences in overall survival were noted between the groups. Furthermore, no drug-related adverse events resulted in discontinuation of sorafenib therapy. Univariate log-rank analysis revealed that sorafenib treatment (P=0.002) and treatment prior to resection (P=0.012) were significantly associated with longer DFS; however, sorafenib therapy (P= 0.027) and tumor size (P= 0.028) were associated with longer DFS by multivariate analysis. Furthermore, sorafenib was well-tolerated and improved DFS in patients with advanced HCC who underwent hepatic resection. Thus, tumor resection followed by sorafenib therapy may represent an effective therapeutic strategy for patients with advanced HCC. This possibility should be confirmed in larger, multicenter studies.

show abstract

Section: Discussionsupporting

confidence: 71%

Section: Univariate Analysiscontrasting

confidence: 56%

Section: Univariate Analysismentioning

confidence: 99%

See 1 more Smart Citation

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence

Liao

Zheng

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Therefore, there is a need for a clinically useful predictor of response during patient selection. Several studies have already reported prognostic factors for patients with unresectable HCC treated by sorafenib [7][8][9][10][11][12]. However, the advantage of our scoring system is that it uses factors that are simple and readily available in routine clinical practice without the need for tissue collection or specialized tests that may be costly.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, because only a limited population can benefit from sorafenib therapy, there is an urgent need for pretreatment prediction of the response or prognosis. Several studies have reported prognostic factors for patients with unresectable HCC treated by sorafenib [7][8][9][10][11][12]. However, an adequate consensus on the prognostic factors has not been sufficiently established.…”

Section: Introductionmentioning

confidence: 99%

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment

et al. 2016

View full text Add to dashboard Cite

Objectives: This study aimed to build a prediction score of prognosis for patients with advanced hepatocellular carcinoma (HCC) after sorafenib treatment. Methods: A total of 165 patients with advanced HCC who were treated with sorafenib were analyzed. Readily available baseline factors were used to establish a scoring system for the prediction of survival. Results: The median survival time (MST) was 14.2 months. The independent prognostic factors were C-reactive protein (CRP) <1.0 mg/dL [hazard ratio (HR) =0.51], albumin >3.5 g/dL (HR =0.55), alpha-fetoprotein <200 ng/mL (HR =0.45), and a lack of major vascular invasion (HR =0.39). Each of these factors had a score of 1, and after classifying the patients into five groups, the total scores ranged from 0 to 4. Higher scores were linked to significantly longer survival (p<0.0001). Twenty-nine patients (17.6%) with a score of 4 had a MST as long as 36.5 months, whereas MST was as short as 2.4 and 3.7 months for seven (4.2%) and 22 (13.3%) patients with scores of 0 and 1, respectively. Conclusions: A novel prognostic scoring sys-

show abstract

Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Should we extend the boundaries?

et al. 2022

View full text Add to dashboard Cite

Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

Cited by 23 publications

References 0 publications

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence

Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment

Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Should we extend the boundaries?

Contact Info

Product

Resources

About